Word

272BIO

Status

Registered

Status Code

700

Status Date

Tuesday, November 1, 2022

Serial Number

79314153

Registration Number

6886491

Registration Date

Tuesday, November 1, 2022

Mark Type

4000

Filing Date

Tuesday, April 13, 2021

Published for Opposition

Tuesday, August 16, 2022

Trademark Owner History

272BIO Limited - Original Registrant

Classifications

40 Custom manufacture of veterinary preparations and medical preparations; custom manufacture of pharmaceutical preparations for veterinary and medical use; custom manufacture of biological preparations for veterinary and medical use; custom manufacture of biotechnological preparations for veterinary and medical use; custom manufacture of medicines including biotherapeutic medicines

5 Veterinary preparations for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; medical preparations for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; pharmaceutical preparations for veterinary and/or medical use for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; biological preparations for veterinary and medical use for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; biotechnological preparations for veterinary and medical use for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; medicines, namely, antibody therapeutic preparations and veterinary vaccines for livestock; biotherapeutic medicines for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals

42 Scientific research and development; biotechnological research and development; biotechnological research and development relating to animals and livestock; biotherapeutic product development; medical and veterinary laboratory services; clinical research in the field of veterinary preparations, biotherapeutic medicines, and antibodies; conducting clinical trials for others; information, advice and consultancy relating to the aforesaid services

272 BIO; TWO HUNDRED SEVENTY TWO BIO; TWO SEVEN TWO BIO

Trademark Events

Mar 14, 2023

Final Decision Transaction Processed By Ib

Feb 22, 2023

Final Disposition Notice Sent To Ib

Feb 22, 2023

Final Disposition Processed

Feb 1, 2023

Final Disposition Notice Created, To Be Sent To Ib

Nov 1, 2022

Notice Of Registration Confirmation Emailed

Nov 1, 2022

Registered-Principal Register

Aug 23, 2022

Notification Processed By Ib

Aug 16, 2022

Official Gazette Publication Confirmation E-Mailed

Aug 16, 2022

Published For Opposition

Aug 12, 2022

Change Of Name/Address Rec'd From Ib

Jul 27, 2022

Notification Of Possible Opposition Sent To Ib

Jul 27, 2022

Notification Of Notice Of Publication E-Mailed

Jul 27, 2022

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jul 14, 2022

Approved For Pub - Principal Register

Jul 14, 2022

Examiner's Amendment Entered

Jul 14, 2022

Notification Of Examiners Amendment E-Mailed

Jul 14, 2022

Examiners Amendment E-Mailed

Jul 14, 2022

Examiners Amendment -Written

Jun 20, 2022

Teas/Email Correspondence Entered

Jun 20, 2022

Correspondence Received In Law Office

Jun 20, 2022

Teas Response To Office Action Received

Jan 23, 2022

Refusal Processed By Ib

Jan 6, 2022

Non-Final Action Mailed - Refusal Sent To Ib

Jan 6, 2022

Refusal Processed By Mpu

Dec 9, 2021

Non-Final Action (Ib Refusal) Prepared For Review

Dec 8, 2021

Non-Final Action Written

Dec 4, 2021

Assigned To Examiner

Jul 2, 2021

Application Filing Receipt Mailed

Jun 28, 2021

New Application Office Supplied Data Entered

Jun 25, 2021

Sn Assigned For Sect 66a Appl From Ib